AIM Study

Uses

Where it comes from

Other

Highlighted claims

• The AIM study is a hybrid I, two-arm, parallel-group, pragmatic randomised controlled trial running from 2023 to 2027. — Study protocol for a hybrid I randomised clinical trial to evaluate an audit and feedback and a pharmacist-led intervention to reduce potentially inappropriate medications in older adults: the AIM study
• The trial requires 170 general practitioners, split evenly between intervention and control groups. — Study protocol for a hybrid I randomised clinical trial to evaluate an audit and feedback and a pharmacist-led intervention to reduce potentially inappropriate medications in older adults: the AIM study
• The study includes three regional health systems in Spain: Mallorca, Tarragona-Reus, and Valencia. — Study protocol for a hybrid I randomised clinical trial to evaluate an audit and feedback and a pharmacist-led intervention to reduce potentially inappropriate medications in older adults: the AIM study
• General practitioners are randomised individually in a 1:1 ratio with central allocation concealment. — Study protocol for a hybrid I randomised clinical trial to evaluate an audit and feedback and a pharmacist-led intervention to reduce potentially inappropriate medications in older adults: the AIM study
• The AIM study tests whether a pharmacist-led audit and feedback intervention can reduce benzodiazepine and PPI prescribing in patients aged 65 or older. — Study protocol for a hybrid I randomised clinical trial to evaluate an audit and feedback and a pharmacist-led intervention to reduce potentially inappropriate medications in older adults: the AIM study